Akari Therapeutics Files 8-K on Shareholder Votes & Financials
Ticker: AKTX · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1541157
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
Related Tickers: AKTX
TL;DR
AKTX filed an 8-K on 12/15/25 covering shareholder votes and financials.
AI Summary
Akari Therapeutics Plc filed an 8-K on December 15, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is incorporated in England and Wales and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides updates on corporate governance and financial reporting for Akari Therapeutics, which could impact investor decisions and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating new material risks.
Key Numbers
- 001-36288 — SEC File Number (Identifies the company's filing history with the SEC.)
- 98-1034922 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc (company) — Former Company Name
- Morria Biopharmaceuticals PLC (company) — Former Company Name
- December 15, 2025 (date) — Date of Report
- England and Wales (jurisdiction) — State of Incorporation
- 2834 (sic_code) — Standard Industrial Classification
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in this excerpt.
What financial statements are being reported?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in this excerpt.
When was Akari Therapeutics Plc formerly known as Celsus Therapeutics Plc?
The date of name change from Celsus Therapeutics Plc was June 21, 2013.
What is Akari Therapeutics Plc's Standard Industrial Classification code?
The SIC code for Akari Therapeutics Plc is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's primary business address?
The company's business address is 401 East Jackson Street, Suite 3300, Tampa, FL 33602.
Filing Stats: 1,208 words · 5 min read · ~4 pages · Grade level 15.3 · Accepted 2025-12-16 16:30:37
Key Financial Figures
- $0.000000005 — tal Market Ordinary Shares, par value $0.000000005 per share* *Trading, but only in conn
Filing Documents
- form8-k.htm (8-K) — 63KB
- 0001493152-25-027969.txt ( ) — 268KB
- aktx-20251215.xsd (EX-101.SCH) — 4KB
- aktx-20251215_def.xml (EX-101.DEF) — 26KB
- aktx-20251215_lab.xml (EX-101.LAB) — 36KB
- aktx-20251215_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: December 16, 2025 By: /s/ Kameel Farag Kameel Farag Interim Chief Financial Officer